Manunga Jesse, Stanberry Larissa I, Alden Peter, Alexander Jason, Skeik Nedaa, Stephenson Elliot, Titus Jessica, Karam Joseph, Teng Xiaoyi, Sullivan Timothy
Department of Vascular and Endovascular surgery, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, 920 E. 28th Street, Suite 300, Minneapolis, MN, 55407, USA.
Minneapolis Heart Institute Foundation, Minneapolis, MN, USA.
CVIR Endovasc. 2019 Oct 27;2(1):34. doi: 10.1186/s42155-019-0075-z.
Endovascular rescue of failed infrarenal repair (EVAR) has emerged as an attractive option to stent graft explantation. The procedure, however, is underutilized due to limited devices accessibility and the challenges associated with their implantation in this patient population. The purpose of this study was to report our outcomes and discuss our approach to rescuing previously failed infrarenal endovascular aneurysm repairs (EVAR) with fenestrated/branched endografts (f/b-EVAR).
A retrospective analysis of prospectively collected data of consecutive patients with failed EVAR rescued with f/b-EVAR at our institution from November 2013 to March 2019 was conducted. The study primary end point was technical success; defined as the implantation of the device with no type I a/b or type III endoleak or conversion to open repair. Secondary endpoints included major adverse events (MAEs), graft patency and reintervention rates.
During this time, 202 patients with complex aortic aneurysms were treated with f/b-EVAR. Of these, 19 patients (Male: 17, mean age 79 ± 7 years) underwent repair for failed EVAR. The median time from failed repair to f/b-EVAR was 48 (30, 60) months. Treatment failure was attributed to stent graft migration in 9 (47.4%) patients, disease progression in 5 (26.3%), short initial neck in 3 (15.8%) and unable to be determined in 2 (10.5%). Three patients were treated urgently with surgeon modified stent graft. Technical success was achieved in 18 patients (95%), including two who had undergone emergent repair for rupture. Seventy-two targeted vessels (97.3%) were successfully incorporated. Sixteen (84.2%) patients required a thoracoabdominal repair to achieve a durable seal. Major adverse events (MAEs) occurred in 3 patients (15.7%) including paralysis and death in one (5.3%), compartment syndrome and temporary dialysis in another and laparotomy with snorkeling of one renal and bypass of the other in the third patient. Median (IQR) hospital length of stay was 3 (2, 4) days. Late reintervention, primary target vessel patency and primary assisted patency rates were 5.3%, 98.6% and 100%, respectively.
Implantation of f/b-EVAR in patients with failed previous EVAR is a challenging undertaking that can be performed safely with a high technical success and low reintervention rates.
肾下修复失败的血管腔内修复术(EVAR)已成为一种比支架移植物取出术更具吸引力的选择。然而,由于设备获取有限以及在这类患者群体中植入相关的挑战,该手术的应用并不充分。本研究的目的是报告我们的治疗结果,并讨论我们使用开窗/分支型腔内移植物(f/b-EVAR)挽救先前失败的肾下腔内动脉瘤修复术(EVAR)的方法。
对2013年11月至2019年3月在我们机构接受f/b-EVAR挽救的连续肾下修复失败患者的前瞻性收集数据进行回顾性分析。研究的主要终点是技术成功;定义为设备植入后无I a/b型或III型内漏或转为开放修复。次要终点包括主要不良事件(MAE)、移植物通畅率和再次干预率。
在此期间,202例复杂主动脉瘤患者接受了f/b-EVAR治疗。其中,19例患者(男性17例,平均年龄79±7岁)接受了失败的EVAR修复。从修复失败到f/b-EVAR的中位时间为48(30,60)个月。治疗失败的原因是支架移植物移位9例(47.4%)、疾病进展5例(26.3%)、初始颈部短3例(15.8%)、2例(10.5%)原因不明。3例患者紧急接受了外科医生改良的支架移植物治疗。18例患者(95%)获得技术成功,其中2例因破裂接受了急诊修复。72条目标血管(97.3%)成功整合。16例(84.2%)患者需要胸腹联合修复以实现持久密封。3例患者(15.7%)发生主要不良事件(MAE),包括1例(5.3%)瘫痪和死亡、另1例骨筋膜室综合征和临时透析、第3例患者剖腹探查,一侧肾气栓形成,另一侧肾旁路手术。中位(IQR)住院时间为3(2,4)天。晚期再次干预、主要目标血管通畅率和主要辅助通畅率分别为5.3%、98.6%和100%。
在先前EVAR失败的患者中植入f/b-EVAR是一项具有挑战性的工作,但可以安全地进行,技术成功率高,再次干预率低。